title: Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
abstract: A 47-year-old man was diagnosed with non-Hodgkin's lymphoma (NHL) follicular B-cell type (stage IVB). Although partial remission was observed after the administration of several combination chemotherapeutic agents, no more improvement was observed. After we finished the FND (fludarabine, mitoxantrone, dexamethasone) regimen, the patient's status improved. After the administration of the FND regimen, thrombocytopenia developed, and the platelet count did not recover to previous levels. After rituximab was administered for the treatment of thrombocytopenia, the platelet count recovered. Then we combined fludarabine and rituximab for the treatment of NHL. Although fludarabine was administered, the platelet count did not decrease when combined with rituximab. In the discussion, we analyze the characteristics and the treatment outcome of the thrombocytopenia induced by fludarabine reviewed in the literature.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tsutsumi
authors.forename: Hiroe
authors.initials: H
authors.lastname: Kanamori
authors.forename: Hiina
authors.initials: H
authors.lastname: Minami
authors.forename: Mio
authors.initials: M
authors.lastname: Musashi
authors.forename: Arata
authors.initials: A
authors.lastname: Fukushima
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ehira
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yamato
authors.forename: Shinji
authors.initials: S
authors.lastname: Obara
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Ogura
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
authors.forename: Nobuo
authors.initials: N
authors.lastname: Masauzi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D016896:Treatment Outcome; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014740:Vidarabine; C024352:fludarabine